Literature DB >> 11410098

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

A B Moscicki1, N Hills, S Shiboski, K Powell, N Jay, E Hanson, S Miller, L Clayton, S Farhat, J Broering, T Darragh, J Palefsky.   

Abstract

CONTEXT: Low-grade squamous intraepithelial lesions (LSILs) have been described as a benign cytological consequence of active human papillomavirus (HPV) replication. Several studies have reported that certain behavioral and biological risks exist for LSIL, suggesting that HPV alone is not sufficient for the development of LSIL. However, because most of these studies have been cross-sectional, it is not known whether behavioral and biological risks are simply risks for HPV infection itself.
OBJECTIVE: To prospectively examine risks of incident HPV infection in HPV-negative females and of incident LSIL development in females with HPV infection.
DESIGN: Prospective cohort study conducted between 1990-2000, with a median follow-up of 50 months. SETTING AND PARTICIPANTS: Females aged 13 to 21 years who attended 2 family planning clinics in the San Francisco bay area; 496 had prevalent HPV infection and 105 were HPV-negative. MAIN OUTCOME MEASURE: Incident development of HPV infection and LSIL, analyzed by various demographic, behavioral, and clinical risk factors.
RESULTS: Fifty-four incident HPV infections occurred in the 105 females who were HPV-negative at study entry (median duration of follow-up for those who remained HPV-negative was 26 months). Multivariable analysis showed that risks of HPV included sexual behavior (relative hazard [RH], 10.10; 95% confidence interval [CI], 3.24-31.50 per new partner per month), history of herpes simplex virus (RH, 3.54; 95% CI, 1.37-9.10), and history of vulvar warts (RH, 2.73; 95% CI, 1.27-5.87). Current use of oral contraceptives had a significantly protective effect (RH, 0.49; 95% CI, 0.28-0.86). Among the 496 individuals who were HPV-positive at baseline or in follow-up, there were 109 incident cases of LSIL during the follow-up interval, with a median follow-up time of 60 months for those who never developed LSIL. Human papillomavirus infection was the most significant risk factor for development of LSIL. The multivariable model showed the following risks for LSIL: HPV infection for less than 1 year (RH, 7.40; 95% CI, 4.74-11.57); HPV infection for 1 to 2 years (RH, 10.27; 95% CI, 5.64-18.69); HPV infection for 2 to 3 years (RH, 6.11; 95% CI, 1.86-20.06); and daily cigarette smoking (RH, 1.67; 95% CI, 1.12-2.48).
CONCLUSION: Our results indicate distinct risks for HPV and LSIL. In addition, most women with HPV infection in our study did not develop LSIL within a median follow-up period of 60 months. These findings underscore the hypothesis that certain biological risks thought to be associated with LSIL are, in fact, risks for acquisition of HPV. Cigarette smoking was a risk specific to LSIL, supporting the role of tobacco in neoplastic development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410098     DOI: 10.1001/jama.285.23.2995

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  140 in total

1.  Cervical intraepithelial neoplasia in women presenting with external genital warts.

Authors:  Michelle Howard; John Sellors; Alice Lytwyn
Journal:  CMAJ       Date:  2002-03-05       Impact factor: 8.262

2.  Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting.

Authors:  Sarah Coseo Markt; Ana C Rodriguez; Robert D Burk; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Martha Hutchinson; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

3.  HPV typing and its relation with apoptosis in cervical carcinoma from Indian population.

Authors:  M Shabbir Alam; Asgar Ali; Syed Jafar Mehdi; Nisreen Sherif Alyasiri; Zakia Kazim; Swaraj Batra; A K Mandal; M Moshahid Alam Rizvi
Journal:  Tumour Biol       Date:  2011-09-20

4.  Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers.

Authors:  Brandon Brown; Magaly Blas; Alejandra Cabral; Cesar Carcamo; Patti Gravitt; Neal Halsey
Journal:  Vaccine       Date:  2012-02-01       Impact factor: 3.641

5.  Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis.

Authors:  Ann N Burchell; Allita Rodrigues; Veronika Moravan; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

6.  Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development.

Authors:  Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky
Journal:  J Med Virol       Date:  2009-04       Impact factor: 2.327

Review 7.  Cervical cancer screening.

Authors:  Dorothy J Wiley; Bradley J Monk; Emmanuel Masongsong; Kristina Morgan
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

8.  Human papillomavirus infections among couples in new sexual relationships.

Authors:  Ann N Burchell; Pierre-Paul Tellier; James Hanley; François Coutlée; Eduardo L Franco
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Zoe R Edelstein; Craig Meyers; Jesse Ho; Mark Schiffman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women.

Authors:  Ann Nielsen; Thomas Iftner; Christian Munk; Susanne K Kjaer
Journal:  Sex Transm Dis       Date:  2009-10       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.